CERO THERAPEUTICS HOLDINGS, INC.

Phoenix Biotech Acquisition Corp, trading under the ticker PBAX and sponsored by Phoenix Biotech Sponsor LLC, completed its SPAC initial public offering in 2021 with a focus on the life sciences and biotechnology sector. The vehicle announced a definitive business combination agreement with Cero Therapeutics, a clinical-stage biopharmaceutical company developing chimeric engulfment receptor T cell, or CER-T, therapies for solid tumor oncology indications. The November 2022 10-Q filing, submitted under the combined entity name Cero Therapeutics Holdings, Inc., reflects the SPAC's de-SPAC transition period ahead of merger close. Visit SpacDesk and sign up for full filing history, timeline data, and deal analytics on PBAX and hundreds of other SPAC transactions.